Respiratory News and Research

RSS

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

Researchers find new drug target for mitochondrial dysfunction

Mitochondria, long known as "cellular power plants" for their generation of the key energy source adenosine triphosphate (ATP), are essential for proper cellular functions. Mitochondrial defects are often observed in a variety of diseases, including cancer, Alzheimer's disease, and Parkinson's disease, and are the hallmarks of a number of genetic mitochondrial disorders whose manifestations range from muscle weakness to organ failure. Despite a fairly strong understanding of the pathology of such genetic mitochondrial disorders, efforts to treat them have been largely ineffective.

28 Mar 2014

New policy report on multi-drug resistant tuberculosis

Leading politicians, officials, researchers and civil society organisations convened in Brussels at the launch of European Voice’s multi-drug resistant (MDR-TB) policy report in the lead up to World TB day, to discuss the rising incidence of MDR-TB, the need for more effective treatments, new vaccines and better diagnostics and what needs to done at a European level to tackle this preventable disease.

28 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

Study points to potential culprit that kills motor neurons in ALS

Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is marked by a cascade of cellular and inflammatory events that weakens and kills vital motor neurons in the brain and spinal cord. The process is complex, involving cells that ordinarily protect the neurons from harm. Now, a new study by scientists in The Research Institute at Nationwide Children's Hospital points to a potential culprit in this good-cell-gone-bad scenario, a key step toward the ultimate goal of developing a treatment.

27 Mar 2014

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Transforming growth factor-beta (TGF-β) type II receptor (TβRII) levels are extremely low in the brain tissue of patients with Alzheimer's disease.

27 Mar 2014

WHO report confirms air pollution as world's largest single environmental health risk

In new estimates released today, WHO reports that in 2012 around 7 million people died - one in eight of total global deaths - as a result of air pollution exposure. This finding more than doubles previous estimates and confirms that air pollution is now the world's largest single environmental health risk. Reducing air pollution could save millions of lives.

25 Mar 2014

State highlights: Fla. employees' unequal premiums; abuse by Calif. doctor alleged

The Florida Cabinet, state agency managers and legislative staff are among 30,000 top-ranked state workers who will continue to pay ultra-low health insurance premiums in the coming year. In a reverse of the Robin Hood principle, the state charges lower-paid workers six times more than those who have the highest earnings pay. ... [B]oth the House and Senate this week released initial budgets that would keep premiums at the same rate (3/22).

25 Mar 2014

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Common cholesterol-lowering drugs could provide relief to patients suffering from a chronic lung disease, a study has shown.

25 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Climate change could increase death rates in London and southeast England, scientists predict

Warmer summers brought on by climate change will cause more deaths in London and southeast England than the rest of the country, scientists predict.

24 Mar 2014

New consensus statements developed to help tackle drug-resistant TB

New consensus statements have been developed to help tackle the growing threat of multidrug-resistant tuberculosis (TB) and extensively drug-resistant tuberculosis (TB).

24 Mar 2014

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.

21 Mar 2014

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

21 Mar 2014

Research roundup: New medical coding system; choosing a hospice; revamping Medicare

On October 1, 2014, all health plans, health data clearinghouses, and health care providers that transmit health information electronically must use a new, significantly broader, coding system, called ICD-10, for diagnoses and inpatient procedures.

21 Mar 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

21 Mar 2014

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Concordia Healthcare Corp., announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

20 Mar 2014

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Adults hospitalised with H1N1 influenza during the 2009–2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a large meta-analysis involving more than 29 000 patients from 38 countries, published in The Lancet Respiratory Medicine journal. The findings also indicate that treatment within 2 days of flu symptoms developing halved the risk of death compared with later treatment or no treatment.

20 Mar 2014

Researchers evaluate exposure to snuff smoke in nonsmokers after launch of second law

Researchers of the Tobaco Control Unit of the Catalan Institute of Oncology (ICO) and the Bellvitge Biomedical Research Institute (IDIBELL) evaluated exposure to snuff smoke in nonsmokers before the entry into force of the first Spanish smoking ban and after the launch of the second law (2011 ) in the city of Barcelona.

19 Mar 2014

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).

19 Mar 2014

Respiratory News and Research

ADMA Biologics reports consolidated net loss of $15.5M in 2013

Researchers find new drug target for mitochondrial dysfunction

New policy report on multi-drug resistant tuberculosis

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Study points to potential culprit that kills motor neurons in ALS

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

WHO report confirms air pollution as world's largest single environmental health risk

State highlights: Fla. employees' unequal premiums; abuse by Calif. doctor alleged

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

FDA approves Xolair for treatment of chronic idiopathic urticaria

Climate change could increase death rates in London and southeast England, scientists predict

New consensus statements developed to help tackle drug-resistant TB

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Research roundup: New medical coding system; choosing a hospice; revamping Medicare

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Researchers evaluate exposure to snuff smoke in nonsmokers after launch of second law

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News